
International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2623 - 2643
Published: March 1, 2025
In recent years, nanobiotechnology, widely used in hepatoma, holds great promise for improving targeted hepatocarcinoma therapy. On account of the unique properties low toxicity, good tolerance, biocompatibility, and biodegradability new nanomaterials, a drug delivery system (TDDS) has been constructed, which can boost therapeutic effect hepatoma-targeted drugs, reduce minimize off target reactions by enhancing permeability retention (EPR) active targeting, thus existing liver cancer therapy strategies. Different nanoparticles have their own advantages disadvantages. They be loaded with multiple drugs on same nanoparticle also surface modified each other to achieve synergistic anti-tumor effects. This essay provides comprehensive overview current status hepatocarcinoma, nanoparticles' structure, disadvantages nanoparticle, application progress cancer. We hope provide basis future clinical hepatoma using nanotechnology.
Language: Английский